Jim Simons' Renaissance Technologies Portfolio: Tech and Healthcare Dominance

Top Holdings

Renaissance Technologies' portfolio, as of March 31, 2026, is dominated by high-value technology and healthcare stocks. The top holdings by total stock value include:

• NVIDIA Corporation (NVDA): $4.41B (6.9% allocation)
• United Therapeutics Corp (UTHR): $1.06B (1.66% allocation)
• Palantir Technologies Inc (PLTR): $1.02B (1.6% allocation)
• Kinross Gold Corp (KGC): $0.78B (1.22% allocation)
• Micron Technology Inc (MU): $0.73B (1.14% allocation)
• Verisign Inc (VRSN): $0.70B (1.09% allocation)
• Exelixis Inc (EXEL): $0.59B (0.92% allocation)
• FRANCO NEV Corp (FNV): $0.55B (0.86% allocation)
• Sandisk Corp (SNDK): $0.51B (0.79% allocation)
• Apple Inc (AAPL): $0.78B (1.22% allocation)

Sector Allocation

The portfolio demonstrates a clear bias towards Technology and Healthcare sectors:

• Technology: Concentrated in NVIDIA, Palantir, Micron, Verisign, and Apple, accounting for approximately 3.84% of the portfolio value.
• Healthcare: Significant allocation to United Therapeutics and Exelixis, representing about 2.58% of the portfolio.
• Basic Materials: Kinross Gold and Franco Nev Corp make up roughly 2.00% of the portfolio.
• Other: Sandisk Corp's sector is unspecified, but it accounts for about 0.79% of the portfolio.

Recent Changes

Several holdings show significant changes from the previous period:

• Apple Inc (AAPL): Experienced a massive increase in shares (+98320.42%) and shares (+3,072,513), indicating a substantial new position.
• NVIDIA Corporation (NVDA): Shares increased by 189.98% (over 1.65 million shares added), reflecting continued confidence in the stock.
• Palantir Technologies Inc (PLTR): Holdings decreased significantly by 20.58% in shares (-1.81 million shares).
• Micron Technology Inc (MU): Holdings saw a sharp reduction of 28.17% (-848,157 shares).
• FRANCO NEV Corp (FNV): Holdings decreased by 10.46% (-259,200 shares).

Investment Strategy Analysis

Renaissance Technologies' portfolio, managed by Jim Simons, appears to employ a highly selective, quantitative-driven approach focused on technology and healthcare sectors. The fund's strategy likely involves:

• Technology Focus: Heavy allocation to leading tech companies like NVIDIA, Apple, and Micron, suggesting confidence in the sector's growth potential.
• Healthcare Exposure: Significant position in United Therapeutics and Exelixis, indicating a bet on healthcare innovation and biotechnology advancements.
• Commodities Play: Allocation to gold mining companies (Kinross Gold) and energy infrastructure (Franco Nev), suggesting diversification into resource sectors.
• Quantitative Edge: The fund's investment strategy likely relies on sophisticated models to identify mispriced assets, as evidenced by the large position in Apple despite its market cap.

The portfolio's structure suggests a long-term investment horizon with a focus on capturing alpha through concentrated positions in high-growth sectors. The fund's performance likely benefits from its unique quantitative edge and selective investment criteria, targeting opportunities where traditional analysis may fall short.